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1. Introduction  
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed 
drug groups. These drugs are used dermally or systemically in treatment of various 
rheumatic diseases, including rheumatoid arthritis (RA), as well as for osteoarthritis, low 
back pain and some joint diseases. The mechanism of action of NSAIDs is reversible 
inhibition of the cyclooxygenase enzyme (COX) and decreasing the synthesis of 
prostaglandins (Lionberger 2010; Massey 2010). However, these drugs lead to unfavorable 
effects specifically on the stomach as a result of inhibition of prostaglandins (PGs), which 
play a role in protection of the gastric mucosa, in systemic administration. The severity of 
these unfavorable side effects may range from a simple ailment like dyspepsia to peptic 
ulcer and gastrointestinal hemorrhage. Furthermore, the acidic character of NSAIDs may 
lead to local irritation and lesions on the gastrointestinal mucosa. Therefore, some NSAIDs 
are administered percutaneously and transdermally to achieve local or systemic effect as an 
alternative to oral and parenteral administration (Heyneman et al., 2000; Hooper et al., 
2004). In dermal administration, the drug substances have to pass the stratum corneum (SC) 
layer to reach lower layers of the skin and/or to enter systemic circulation. In this context, 
formulation of the product may play a key role for penetration and absorption of the active 
ingredient (Lee & Maibach, 2006). Several formulation approaches for cutaneous 
administration of NSAIDs have been employed. The conventional pharmaceutical forms 
particularly used for dermal administration to achieve local effect are gels, creams and 
ointments (Williams, 2003). Furthermore, studies on novel drug delivery systems are 
available for transdermal administration of NSAIDs. These new approaches include liquid 
crystals, nano/micro emulsions, liposomes, solid lipid particles and patches. These systems 
are used to enhance cutaneous passage of drugs into systemic circulation and to target 
different layers of the skin (Guy, 2010; Santos et al., 2008; El Maghraby et al., 2008; Ceve, 
2004). Different approaches have been performed to enhance cutaneous passage of drugs 
with the objective of overcoming the low skin permeability (Guy, 2010; Tromer & Neubert, 
www.intechopen.com
 
Rheumatoid Arthritis – Treatment 
 
26
2006). The most frequently used approach is to include penetration enhancers in 
formulations. In addition to penetration enhancers, there are studies available in which 
physical methods such as iontophoresis is used in improving of skin delivery of drugs (Guy, 
1996; Benson, 2005; Williams, 2003). 
The chapter deals with the classification and mechanisms of action of NSAIDs used in 
treatment of various rheumatic diseases as well as for osteoarthritis, low back pain and 
some joint diseases. The advantages of skin delivery of NSAIDs to target affected tissues 
and/or to achieve systemic effect are also emphasized. In particular, recent studies in which 
novel drug delivery systems were developed for dermal and transdermal administration of 
NSAIDs are summarized. 
2. Non-steroidal anti-inflammatory drugs (NSAIDs) 
2.1 General view and classification of NSAIDs 
NSAIDs are used for chronic inflammatory conditions such as rheumatoid arthritis and 
osteoarthritis, posttraumatic conditions (e.g. distortion, contusion), for relieving mild to 
moderate pain of varied origin, reducing fever, as well as for preventing local inflammation 
such as gout (Hinz & Brune, 2008; Lionberger et al.,  2011; Patrono & Rocca, 2009). NSAIDs 
are employed in systemic as well as local dosage forms particularly for musculoskeletal pain 
and patients with inflammatory joint disorders. NSAIDs possess antipyretic effect in 
addition to analgesic-anti-inflammatory actions. NSAIDs may be responsible for side effects 
such as acute renal failure, undesirable central nervous effects, e.g. dizziness, allergic 
reactions and fluid retention in the body. Beside some side effects of NSAIDs mentioned 
before, NSAIDs lead to unfavorable effects on the stomach as a result of inhibition of 
prostaglandins, which play a role in protection of the gastric mucosa, in systemic 
administration e.g. oral, parenteral. The severity of this unfavorable gastrointestinal side 
effect may range from a simple ailment like dyspepsia to gastric bleeding potentially 
resulting in admission to hospital, necessitating surgery or even resulting in death 
(Hooper et al., 2004). Furthermore, the acidic character of NSAIDs may lead to local 
irritation, and lesions on the gastrointestinal mucosa are known as NSAIDs gastropathy 
(Heynemann et al., 2000). Within the past 20 years many COX inhibitors were removed 
for undesired drug effects shortly after entering the market e.g. benoxaprofen and 
isoxicam (Brune et al.,  2010). Therefore, some NSAIDs are administered percutaneously 
to achieve local or systemic effect as an alternative to oral and parenteral administration 
(Heyneman et al., 2000; Hooper et al., 2004). NSAIDs are classified by their chemical 
structures as shown in Table 1.  
2.2 Mechanism of anti-inflammatory effect of NSAIDs 
NSAIDs usually act through decreasing reactions of inflammation that is accompanied with 
pain. It is known that prostaglandin (PG) derivatives, that are formed from arachidonic acid 
through COX enzyme, play an important role in formation of inflammation, and that the 
PGE1 and PGE2 levels are increased in the synovial fluid in patients with rheumatoid 
arthritis. All NSAIDs inhibit the COX enzyme and act through decreasing the synthesis of 
PGE2, PGD2, PGF2 , PGI2 and thromboxane A2 (TxA2) and prostacycline (Lionberger et al., 
2010; Massey et al., 2010). Two isoforms of COX (COX-1 and COX-2) were identified and  
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studies of their regulation and sites of expression led to the hypothesis that it is the 
molecular target for the anti-inflammatory and analgesic effects of NSAIDs. COX-1 is 
important for production of gastric mucus and maintenance of renal blood flow. On the  
other hand, COX-2 is induced by several cytokines, growing factors and endotoxins and 
plays a role in the inflammatory process observed at the site of inflammation. Nonselective 
NSAIDs inhibit both COX-1 and COX-2, and the current hypothesis is that COX-2 inhibition 
is responsible for the anti-inflammatory effects of NSAIDs, whereas COX-1 inhibition is 
responsible for some other undesired side effects, in particular for gastrointestinal toxicity. 
Therefore selective inhibition of COX-2 may prevent undesirable gastrointestinal effects of 
NSAIDs. The discovery and clinical development of selective COX-2 inhibitors (COXIBs) 
were achieved in the early 1990s. COXIBs have anti-inflammatory effects without side 
effects on the stomach as compared to traditional NSAIDs. However, these new NSAIDs 
also possess some side effects, since inhibition of COX-2 affects kidney function and blood 
pressure and possibly other physiological parameters (Brune & Hinz, 2004; Marnett, 2009; 
Patrono & Rocco, 2009; Mitchell et al., 1994). Rofecoxib and valdecoxib was withdrawn from 
the market due to serious cardiovascular side effects, and lumiracoxib was removed from 
several markets for serious liver toxicity unrelated to COX-2 inhibition. Celecoxib has been 
marketed in the United States, and celecoxib and etoricoxib was marketed in Europe (Hinz 
& Brune, 2008). 
2.3 Physicochemical properties of NSAIDs 
Table 2 demonstrates the open chemical formulas and physicochemical properties of 
NSAIDs, which have dermal and transdermal commercial preparations and of the 
molecules which are potential candidates in this group. 
The physiochemical properties of drugs are important in dermal and transdermal 
administration (Potts and Francoeur, 1991; Kalia et al., 1998; Prausnitz & Langer, 2008). The 
ideal candidate drugs  have the following properties: water-solubility (> 1 mg/ml), 
lipophilicity (log P= 1-3), low molecular weight (< 500 Dalton) and low melting temperature 
(< 200°C) (Guy, 2007). As can be seen in Table 2, all drugs  are under 400 Dalton. The Log P 
values, which indicate lipophilic characteristics of pharmaceuticals, vary between 2.0 and 3.8 
except for flurbiprofen, etofenamate and lumiracoxib. In other words, they have medium 
lipophilicity. Other NSAIDs except meloxicam and tenoxicam have a melting point under 
<200°C. Due to these physicochemical properties, NSAIDs are ideal molecules for dermal 
administration. As a matter of fact, dermal/transdermal commercial preparations of most of 
NSAIDs are available in pharmacies. Studies on development of skin delivery systems of 
other molecules are in progress. 
3. Dermal and transdermal administration of NSAIDs 
3.1 Skin transport 
Human skin is the largest organ in our body with its size about 1.8-2.0 m2. It is a well-
engineered organ that protects organism against environmental factors and regulates heat 
and water loss from the body. It is also easily accessible due to its large surface area. 
Therefore, it offers an ideal application site to deliver therapeutic agents for both local and 
systemic actions. The skin consists of three main layers; the epidermis, the dermis, and the 
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hypodermis. In particular, stratum corneum (SC), the outermost layer of epidermis is formed 
by dead and keratinized cells, and thus it is a unique barrier to passage of drugs through the 
skin (Williams, 2003).The drug substances from dermal or transdermal formulations have to 
pass through the SC layer to reach lower layers of the skin and/or to enter systemic 
circulation. The physicochemical characteristics of drug molecules and the types of the 
formulations are an effective factor in both dermal and transdermal delivery (Hadgraft, 
1999). The drugs pass through the skin via three different routes, which are transcellular, 
intercellular and/or transappendageal (shunt) routes (sweat glands, hair follicles, sebaceous 
glands) (Williams, 2003). 
3.2 The superiorities and limitations of dermal and transdermal delivery  
There are two pharmacological approaches in dermal administration of drugs, which are 
dermal and transdermal. In dermal administration, the applied formulation ensures 
localization of drugs in dermal layers. In transdermal administration, the drugs reach the 
dermis of skin via carrier systems and then go into systemic circulation (Williams, 2003). 
In dermal administration, the access of drugs to systemic circulation is prevented or 
minimized. Therefore, the systemic adverse effects of drugs are avoided. The advantages of 
transdermal administration include high patient compatibility with treatment, ability to 
discontinue treatment any time necessary, delivery of drug to organism at a controlled rate, 
ensuring fixed plasma drug level and eliminating the hepatic first-pass effect (Guy, 1996). 
NSAIDs administered dermally and transdermally penetrate slowly and in small 
quantities into the systemic circulation. These approaches also prevent high local drug 
levels in the alimentary tract and direct toxicity of NSAIDs e.g. vomiting, dyspepsia. 
Systemic administration of NSAIDs may cause drug-drug interactions. NSAIDs cause 
fluid retention in the body and may decrease efficacy of antihypertensive agents. 
Furthermore, dermal and transdermal formulations have better patient compliance (non-
invasiveness) and they can be self-administered (Guy, 1996; Taner & Marks, 2008; 
Heynemann et al., 2000). It was reported that the use of dermal NSAIDs may have led to a 
reduction in the total daily dosage of systemic NSAIDs. This would cause an increment in 
side effects of NSAIDs in long term treatment (Sift Carter et al., 1997). Finally, dermally 
applied NSAIDs have a superior safety profile to oral formulations. Adverse effects 
secondary to dermal NSAID application occur in approximately 10 to 15% of patients and 
are primarily cutaneous in nature (rash and pruritus at the site of application 
(Heynemann et al., 2000)). NSAI drug concentration should reach therapeutic level in the 
synovial tissue, synovial fluid and intra-articular tissues during dermal application of 
NSAIDs. There are a number of factors that influence skin absorption of drugs. The 
greatest challenge for dermal penetration is SC, the uppermost layer of the skin, which as 
mentioned previously is the rate limiting step for epidermal drug transport. Therefore 
several formulation approaches are developed to improve its impermeability 
characteristics. 
3.3 Overcoming the barrier properties of the skin 
Several chemical and physical approaches are used to overcome the barrier property of the 
skin in dermal and transdermal administration of drugs. The most frequently used 
approach is to include chemical penetration enhancers in formulations. Recently, physical  
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Substance Chemical Formula 
Molecular 
Weight 
(g/mol) 
Predicted 
Log P 
Melting 
Point 
Predicted 
aqueous 
solubility 
(µg/ml) 
pKa References 
Benzydamine 309,4 3.71 160° (bp)
 
- 
 
9,27 
Avdeef  et 
al., 1998. 
Quane et 
al.,1998 
Bufexamac 223,3 2,43 154°C 110 µg/ml 9,24 
Hadgraft et 
al., 2000 
Celecoxib 381,4 3,5 
157-
158°C 
3,3 µg/ml 11.1 
http:// 
www.drug
bank.ca 
Diclofenac 296,1 3,28 157°C 12 µg/ml 4,18 
Hadgraft et 
al., 2000 
Etodolac 287,4 2,5 145°C 16 µg/ml 4,65 
http:// 
www.drug
bank.ca 
Flurbiprofen 224,3 4,12 110,5°C 2,7 µg/ml 4,14 
Hadgraft et 
al., 2000 
Table 2. Chemical formulas and physicochemical properties of NSAIDs. 
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Substance Chemical Formula 
Molecular 
Weight 
(g/mol) 
Predicted 
Log P 
Melting 
Point 
Predicted 
aqueous 
solubility 
(µg/ml) 
pKa References 
Etofenamate 369,3 4.99 
130–
135°C 
(bp) 
Practically 
insoluble 
in water 
- 
http:// 
www.chem
base.com 
Felbinac 212,2 3,26 164°C 8 µg/ml 4.3 
Pygall et 
al., 2009 
Ibuprofen 206,3 3,72 76°C 14 µg/ml 4,41 
Hadgraft et 
al., 2000 
Indomethacin 357,8 3,10 155°C 25 µg/ml 4,18 
Hadgraft et 
al., 2000 
Ketoprofen 254,3 2,81 94°C 150 µg/ml 4,23 
Hadgraft et 
al., 2000 
Ketorolac 255,3 2,1 
165-
167°C 
(trometh
amine 
salt) 
25 mg/mL 
(trometha
mine salt)
3,5 
http:// 
www.drug
bank.ca 
Lumiracoxib 293,7 4,56 
139-
141°C 
5,49 µg/ml 15,87 
http:// 
www.drug
bank.ca 
Table 2. Continued. 
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Substance Chemical Formula 
Molecular 
Weight 
(g/mol) 
Predicted 
Log P 
Melting 
Point 
Predicted 
aqueous 
solubility 
(µg/ml) 
pKa References 
Meloxicam 351,4 1,9 
242 - 
250°C 
7,15 µg/ml 4,08 
http:// 
www.drug
bank.ca 
Naproxen 230,3 3,00 155,3°C 23 µg/ml 4,4 
Hadgraft et 
al., 2000 
Nimesulide 308,3 
2,56 
 
1,79 
143-
144°C 
18,2 µg/ml 6,46 
http:// 
www.drug
bank.ca 
Oxyphen-
butazone 
324,4 
2,79 
 
3,83 
96°C 256 µg/ml 9,29 
http:// 
www.drug
bank.ca 
Piroxicam 331,4 1,46 199°C 870 µg/ml 13,92 
Hadgraft et 
al., 2000 
Suprofen 260,3 
3,16 
3,53 
124,3°C 42,2 µg/ml 3,91 
http:// 
www.drug
bank.ca 
Table 2. Continued. 
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Substance Chemical Formula 
Molecular 
Weight 
(g/mol) 
Predicted 
Log P 
Melting 
Point 
Predicted 
aqueous 
solubility 
(µg/ml) 
pKa References 
Salicylic acid 138,1 2,4 158°C 2,24 g/mL 2,97 
http:// 
www.drug
bank.ca 
Tenoxicam 337,4 
1,82 
1,22 
211°C 277 µg/ml 13,63 
http:// 
www.drug
bank.ca 
Tiaprofenic 
acid 
260,3 2,42 96°C 450 µg/ml 4,05 
Hadgraft et 
al., 2000 
Valdecoxib 314,4 
3,32 
2,82 
162-
164°C 
34,8 µg/ml 9,4 
http:// 
www.drug
bank.ca 
Table 2. Continued. 
methods such as iontophoresis that enhance penetration of drug molecules through the skin 
are applied (Mitragotri et al., 2000; Tao & Desai, 2003). Furthermore, vesicular carriers, 
microemulsions, lipidic and polymeric particulate carrier systems ensure dermal 
administration of drugs by dermal targeting and enterance of drugs into systemic 
circulation (Neubert, 2011; Benson, 2005). 
3.3.1 Chemical enhancers 
Chemical penetration enhancers reversibly change the structure of the skin to improve the 
flux of drugs through the skin. The mechanism of action of penetration enhancers is 
explained by Lipid-Protein-Partition (LPP) Theory (Williams & Barry, 1991). According to 
this theory, penetration enhancers i) disrupt the lipid structure in intercellular domain of SC, 
or ii) denature or change the conformation of keratin in the intracellular domain and/or iii) 
improve drug partition to SC and thus establish a drug reservoir in SC to act (Williams &  
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NSAIDs Enhancers Results Refs 
Diclofenac Oleic acid(OA)/ 
d-limonene 
Addition of the mixture of oleic acid/d-
limonene as enhancer into diclofenac sodium 
formulations has been found to be effective 
for the dermal and subdermal injuries. 
Escribano et al., 
2003 
Diclofenac Dimethyl sulfoxide 
(DMSO) 
Dermal administration of diclofenac 
containing DMSO vehicle has been found to 
be effective for knee osteoarthritis, and has 
showed better tolerability than oral 
diclefenac. 
Simon et al., 2009 
Etodolac terpenes Gel containing anethol increased absorption 
of etodolac (1,5-fold) significantly in excised 
rat skin, as compared to control gel. 
Taş et al., 2007 
Flurbiprofen 
(nitro ester) 
Transcutol®/(OA) 
lauroglycol 
isopropyl myristate 
(IPM) 
The efficacy and safety of dermal nitro ester 
of flurbiprofen was shown with lipophilic 
ointment containing chemical enhancers. 
Minghetti et al., 
2003 
Flurbiprofen Turpentine oil  The bioavailability of transdermal patch 
formulation flurbiprofen containing 
turpentine oil has been shown to increase 
5.56 times with respect to its oral 
administration. 
Charoo et al., 2008 
Flurbiprofen l-menthol/ethanol Flurbiprofen gel containing ethanol (25%)  
and l-menthol (3%) has showed high in vivo 
absorption rate in rabbits. 
Morimoto et al., 
2000 
Flurbiprofen Linoleic acid (LA)/ 
/linolenic acid 
(LNA)/(OA)  
Palmitic acid (PA) 
Fatty acids (PA, OA, LA, and LNA) extracted 
from Botryococcus braunii was found 
effective enhancers to improve the skin 
delivery flurbiprofen. 
Fang et al., 2004 
Ibuprofen Ethanol The flux of ibuprofen was increased by the 
ethanol (>10-fold flux enhacement) across 
silicone membrane and human skin. 
Watkinson et al., 
2009 
Ibuprofen Propylene glycol 
(PG) 
PG and (PG: water) systems has increased 
the fluxes of ibuprofen due the increase in 
skin partition of ibuprofen. 
Watkinson et al., 
2008 
Ketorolac DMSO/d-limonene 
eucalyptus oil/ 
Transcutol® 
Eucalyptus oil has showed the highest 
permeation enhancer effect for the transdermal 
delivery of ketorolac across rat skin. 
Amrish & Kumar, 
2009 
Ketorolac 
trometamol 
IPM/ Brij 92 Dermal formulations of ketorolac trometamol 
containing Brij 92 exhibited less gastric side 
effect and higher anti-inflammatory effect 
than that of containing IPM. 
El-Setouhy & El-
Ashmony, 2009 
Lumiracoxib OA Oleic acid (10%) has increased the flux of 
lumiracoxib through skin and its retention in 
viable epidermis. 
Moreira et al., 2010 
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NSAIDs Enhancers Results Refs 
Meloxicam N-methyl 
pyrrolidone (NMP)  
Meloxicam gel containing NMP as a 
solubilizer exhibited significant higher anti-
inflammatory in rats compared to 
commercial gel formulation.  
Bachhav & 
Patravale, 2010 
Nimesulide OA/ Transcutol® Oleic acid (3%) in the presence of 
Transcutol® (30%) has led to a significant 
increase in permeation of drug across the 
skin. 
Gungor & 
Bergisadi, 2004 
Piroxicam Lauric acid 
/OA/LA/LNA 
All enhancers showed similar extent of 
permeation, which was 3-fold higher than 
that of without enhancer 
administration. 
Santoyo & 
Ygartua, 2000 
Tenoxicam OA/LA/oleyl 
alcohol 
The highest tenoxicam flux was obtained by 
the addition of fatty acids at 3% 
concentration to PG. 
Gwak & Chun, 
2002 
Tiaprofenic 
acid 
terpenes Gel containing d-limonene increased 
absorption of tiaprofenic acid (6-fold) 
significantly in excised pig skin, as compared 
to control gel. 
Okyar et al.,  2008 
Tiaprofenic 
acid 
terpenes Gel containing d-limonene increased 
absorption of tiaprofenic acid (6-fold) 
significantly in excised rat skin. Gel with 
d-limonene increased tiaprofenic acid skin 
absorption of 10-fold in  
vivo in rats, as compared to control  
gel.  
Okyar et al., 2010 
Table 3. Effect of chemical penetration enhancers to increase skin permeation of NSAIDs. 
Barry, 2004; Thong HY et al., 2007). Co-solvents such as alcohols, oil alcohols, propylene 
glycol, diethyleneglycol monoethylether (Transcutol), and compounds like fatty acids 
terpenes, Azone, dimethylsulfoxide (DMSO), pyrrolidones, urea and surfactants are 
frequently included in dermal/transdermal formulations as penetration enhancers 
(Williams & Barry, 2004; Mohammed et al.,  2007). Table 3 summarizes the penetration 
enhancers to improve passage of NSAIDs through the skin and the results obtained. 
3.3.2 Physical enhancement  
Iontophoresis is one of the most frequently used physical methods in improving dermal 
penetration of drugs. Iontophoresis enhances dermal penetration of drug molecules by 
applying low levels of electrical currents (0,5 mA/cm2) (Marro et al., 2002). Unlike passive 
diffusion-based transdermal administration, particularly, iontophoresis ensures dermal 
penetration of polar and charged drug molecules in high amounts loaded (Kalia et al., 1998; 
Sieg & Wascotte, 2009).  
There are studies investigating whether the iontophoresis technique enhanced dermal 
penetration of NSAIDs. Curdy et al. (2001) dermally administered a commercial gel 
formulation containing piroxicam, and studied dermal penetration of piroxicam by using 
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both passive and iontophoresis method. They found that application of low electric current 
enhanced uptake of piroxicam to SC layer. Moreover, a high piroxicam concentration was 
obtained in the SC, live epidermis and dermis with the iontophoresis application. Mathy 
and coworkers studied the percutaneous penetration of flurbiprofen on hairless rats (Mathy 
et al., 2005). They investigated the flurbiprofen concentrations in the dermal and 
subcutaneous tissue following administration of iontophoresis. The data obtained 
demonstrated that application of iontophoresis ensured delivery of flurbiprofen at a high 
input rate to the dermis and underlying tissues at significant amounts, while maintaining 
low plasma exposure. 
4. Conventional formulations and novel approaches in dermal and 
transdermal delivery of NSAIDs 
Conventional dosage forms of NSAIDs which are commercially available and and possible 
novel carrier systems of NSAIDs to improve their dermal and transdermal delivery are 
summarized in Fig. 
 
 
Fig. 1. Schematic representation of the novel and conventional dermal drug delivery systems. 
4.1 Conventional formulations 
The classical dosage forms of NSAIDs for dermal use that are commercially available are 
usually gels, creams, ointments and lotions. Table 4 gives a list of NSAIDs which have 
commercial dermal preparations. 
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NSAIDs Formulation type
Benzydamine Gel, cream
Felbinac Gel
Bufexamac Cream, ointment, lotion, emulgel 
Diclofenac epolamine Patch
Diclofenac sodium Gel, spray gel
Diclofenac potassium Gel 
Diclofenac diethylammonium Gel, emulgel 
Etofenamate Gel, cream
Ibuprofen Gel, cream
Ketoprofen Gel
Naproxen Gel
Nimesulide Gel
Piroxicam Gel
Salicylic acid Cream, ointment,  lotion
Table 4. Commerical dermal formulations of NSAIDs (Micromedex, electronic version, Rx 
MediaPharma 2011). 
4.1.1 Gels 
They are two-component semi-solid drug carriers that contain high levels of fluid and 
viscosity enhancing agents. Polar solvents such as water and alcohol are used in the liquid 
phase. They contain appropriate viscosity enhancers depending on the physicochemical 
properties of drug molecule and its compatibility with the vehicle. Simple gels are prepared 
with a natural polymer, such as carrageen, pectin or sodium alginate, or semi-synthetic 
stabilizers like cellulose derivatives or synthetic stabilizers like Carbomers (Williams, 2003). 
As can be seen on Table 3, gel formulations of most of NSAIDs are commercially available 
because gels are easy to administer, forming a thin film coating on the skin and ensuring 
rapid action without giving an oily feeling. They are preferred by patients due to these 
advantages. Besides they are cost-efficient since formulation inputs are less, and they are 
preferred by manufacturers. Although there are not commercially available dermal 
formulations of NSAIDs there are studies on development of gel-type formulation of 
tiaprofenic acid (Okyar et al., 2008 and 2010), meloxicam (Martinez et al., 2007; Jain & 
Pathak, 2010; Gupta et al., 2002), aceclofenac (Dua et al., 2010) and flurbiprofen (Minghetti et 
al., 2003; Pandey et al., 2009).  
4.1.2 Ointments, creams and lotions 
Ointments are semi-solid preparations administered on the skin. Their formulations contain 
high levels of oil. Typically they have an occlusive action on the skin, and are used for dry 
lesions. Creams have an emulsion structure although they are defined as semi-solid carrier 
systems. Emulsions are systems consisting of two phases containing water and oil, where 
one is disperse in the other. Creams are more acceptable for patients as they have lower 
viscosity than ointments and are less oily. Lotions are creams with less viscosity (Williams, 
2003). There are cream and/or ointment-type preparations of benzydamine bufexamac, 
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etofenamate, ibuprofen and salicylic acid that are commercially available. Lotion-type 
preparations of bufexamac and salicylic acid are used in treatments (Table 4).  
4.2 Novel formulation approaches for improving skin delivery of NSAIDs 
4.2.1 Micromemulsions 
Microemulsions are transparent liquid dispersions with a droplet size of 20-200 nm. Their 
formulations include four fundamental components, which are water, oil, surfactant and 
co-surfactant. The advantages of microemulsions include enhancing solubility of drugs, 
thermodynamic stability, ease of preparation and low costs (Neubert, 2011). 
Microemulsions have recently attracted attention in enhancing dermal permeation of 
lypophilic drugs as well as hydrophilic drugs. The oils and surfactants included in the 
composition of microemulsions also act as penetration enhancers. Besides, the 
composition of formulation and the internal structure of phases enhance diffusion of the 
drug inside the carrier and improve the partition of drug to SC (Kogan & Garti, 2006). The 
most important disadvantage of microemulsions is potential risk of skin irritation due to 
their high content of surfactants. Kantarcı et al. (2007) prepared microemulsion 
formulations containing diclofenac sodium, and optimized it in with vitro tests. The 
irritant effect of formulations was investigated on healthy volunteers, and their safety was 
demonstrated. In another study, lecithin microemulsions of ketoprofen were developed 
(Paolino et al., 2002). Permeation of drug from microemulsion formulation was compared 
to the conventional dermal ketoprofen formulation. In this study performed with healthy 
volunteers, it was demonstrated that ketoprofen microemulsions enhanced the 
permeation of drug and has good skin tolerability (Amrish & Kumar, 2009). Dalmora et al. 
(2001) administered microemulsions loaded with piroxicam to rats in vivo, and 
demonstrated that dermal anti-inflammatory effect was extended, and inflammation 
inhibition lasted for nine days following single-dose administration. In vivo anti-
inflammatory activity study has also demonstrated that microemulsions containing 
flurbiprofen performed better than conventional gel formulation (Ambade et al., 2008). In 
another study, nano/submicron emulsions of flurbiprofen were suggested as dermal 
carriers (Fang et al., 2004). 
4.2.2 Vesicular carriers 
Vesicular systems such as liposomes, niosomes and transfersomes have been developed for 
optimization of dermal penetration of drugs and particularly for dermal targeting. Vesicular 
systems have the advantages of controlling release rate of the active ingredient and to 
ensure localization of dermally administered drugs in dermal layers. Besides, transdermal 
administration of vesicular systems helps to carry drug molecules into systemic circulation 
(El Sayed et al., 2007; Ceve, 2004). 
4.2.2.1 Liposomes 
Liposomes are described as lipidic vesicles containing water. Cholesterol and phospholipids 
or amphiphilic ingredients of these compounds are typically used as lipids. Liposomes can 
capture hydrophilic molecules or contain lipophilic molecules in their membranes. Some 
liposomes can be adsorbed in the skin surface or may go into fusion. Fusion of liposomes 
may increase the drag force required for permeation of the molecule and facilitate dermal 
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penetration of the drug. However, fusion of liposomes on the skin surface does not apply for 
macromolecular drugs. Another mechanism is penetration of liposomes to SC before fusion 
with SC lipids and releasing the drug there. With this mechanism, particularly the drug in 
liposomes that are dermally administered can be localized in different layers of the skin (El 
Magraby et al., 2008; Williams, 2003). 
Mezei & Gulasekharam (1980) used liposomes as “dermal drug carrier system” for the first 
time. However, liposomes are localized in the outermost layer of the skin (SC). Therefore, it 
is advantageous in cases where retaining drug in SC is desirable. It does not seem possible 
with these systems to penetrate the drug to deeper tissues of the skin or into systemic 
circulation. Therefore, it is rather preferred to increase dermal moisture for cosmetic 
purposes (El Magraby et al., 2008; Williams, 2003). 
4.2.2.2 Niosomes 
Niosomes are liposomes prepared with non-ionic surfactants. Dermal penetration of 
niosomes depend on i) potential penetration-enhancing activity of surfactants in its content, 
ii) penetration of the vesicle to SC, iii) accumulation of vesicle on the skin surface and/or 
increasing thermodynamic activity of the drug on the skin surface. These mechanisms 
depend on the physicochemical properties of the drug, the vesicle and the lipids used (Choi 
& Maibach, 2005; Williams, 2003). Niosomes are the vesicular systems that are most studies 
in dermal and transdermal formulations of NSAIDs. This is because niosomes prevent 
transepidermal water loss, and they act on the lipid structure in the intracellular domain 
with the effect of high amount of surfactant in their content and overcome the barrier 
characteristic of the SC layer. 
It has been observed that dermal retention and dermal penetration of the drug was 
enhanced with dermally administered noisome formulation of nimesulid. Besides, it has 
been determined that the noisome formulation has a faster anti-inflammatory activity than 
the commercial gel formulation (Shahiwala & Misra, 2002). Manosroi et al. (2008) obtained a 
higher flux of the drug in SC and deeper dermal tissues (live epidermis and dermis) with 
elastic noisome formulations loaded with diclophenac diethylammonium. Niosome-like 
vesicles consisting of hydrated mixtures of cholesterol and non-ionic surfactants are defined 
as “proniosomes” (Alsarra et al., 2005; Ammar et al., 2011). Alsarra et al. (2005) 
demonstrated that proniosomes of ketorolac improves permeation of the drug and shortens 
its lag time. In another study, formulations of proniosome were developed for transdermal 
delivery of tenoxicam. It has been stressed that proniosome formulation loaded with 
tenoxicam had higher anti-inflammatory and analgesic effect than the commercially 
available tenoxicam tablets (Ammar et al., 2011). 
4.2.2.3 Transfersomes 
Transfersomes are defined as elastic vesicles that can be highly deformed. They are the first 
generation of elastic vesicles that contain phospholipids and an edge activator. Classical 
liposomes have a diameter varying from 200 to 400 nm, which is too large to pass through 
SC. However, transfersomes reach deeper dermal tissues and even the systemic circulation 
with their elasticity and highly deformable structure (Benson, 2009). It has been 
demonstrated that as classical liposomes cannot be deformed in the same way, 
transfersomes ensure higher skin permeation than liposomes in an in vitro comparison of 
skin permeation of transfersomes and liposomes loaded with meloxicam (Duangjit et al., 
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2011). In the same study, the structure of the skip was studied after administration of 
transfersomes, and it has been found that the structure of lipids in SC was disrupted. 
4.2.2.4 Ethosomes 
Ethosomes contain phospholipids like classical liposomes; however, they also contain high 
levels of alcohol. It has also been demonstrated that its components can reach deeper layers 
of the skin or enter into systemic circulation. Action mechanisms of these carriers in 
improving permeation is explained by their alcohol content as penetration enhancers as well 
as disruption of intercellular lipid structure of SC by the phospholipids in their content 
(Godin & Touitou, 2003;  Williams, 2003). Barupal et al. (2010) prepared ethosomes to 
investigate dermal administration of aceclofenac. They demonstrated that ethosomes have a 
high drug loading capacity and a good stability. 
4.2.3 Nano carriers (Solid lipid nanoparticles-SLN, nanostructured lipid carriers-NLC, 
and nanocapsules) 
It is observed that SLN and NLC formulations have been developed in the last decade for 
their desirable properties in terms of transdermal administration. SLN are water-in-oil 
emulsions containing solids as oil phase, and are prepared from solid lipids or from blends 
of these lipids. NLCs are new generation lipid particles, which have been developed to 
overcome certain disadvantages of SLNs, such as limited drug loading capacity, gellification 
risk and drug leakage due to lipid polymorphism during storage. NLCs contain mixtures of 
different solid lipids blended with liquid oils. The most important advantage of these 
carriers is their low risk of toxicity. Small size of lipid particles ensures close contact with 
SC, and may enhance dermal penetration of drug. 
Polymeric nanoparticles are also prepared from biologically degradable or non-degradable 
polymers. The ability of polymeric particles to improve penetration of drugs and their 
dermal/transdermal applications to target accumulation in different layers of the skin are 
studied. However, dermal/transdermal administration of polymeric particles have been less 
studied than lipidic particles. Table 5 summarizes the studies in the literature on nano-
carriers of NSAIDs that are dermally and transdermally administered. 
4.2.4 Transdermal patches 
Transdermal patches are drug carriers that contain an adhesive layer and ensure access of 
drugs to systemic circulation with controlled release rate. Additionally, the adhesive layer 
provides a firm contact for the drug to the skin. In general, transdermal patches are 
classified into two main groups by their methods of formulation, which are membrane-type 
(reservoir type) and matrix-type. In the former formulation, drug is contained in the 
adhesive and the drug release rate is controlled by the membrane. In the latter, drug 
molecules are dispersed or dissolved in polymer matrix. In cases where the matrix is not 
self-adhesive, a special adhesive layer is added. In transdermal patches, formulation 
components should be compatible with the skin, and they should be chemically stable and 
appropriate for use in combination (Padula et al., 2007; Vasilev et al., 2001; Williams, 2003). 
Among NSAIDs, adhesive types of transdermal patch formulations of meloxicam have been 
developed and evaluated in vitro/in vivo (Ah et al., 2010). In vivo anti-inflammatory 
activity of the formulation was compared to the piroxicam patch using adjuvant arthritis 
model. In conclusion, the meloxicam patch had a better anti-inflammatory effect. In another 
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study, pharmacokinetic data obtained with dermally administered ketoprofen patch was 
compared to the data of gel formulation. The obtained plasma level of ketoprofen was 
demonstrated to be higher than the gel formulation (Mazieres, 2005).  
 
NSAIDs Nano carrier Results Refs 
Celecoxib NLC based gel Gel formulations of celecoxib prepared with NLC 
exhibited fasted drug input and sustained anti-
inflammatory activity up to 24 h. 
Joshi & 
Patravale, 2008 
Flufenamic acid Poly(lactide-co-
glycolide) 
nanoparticles 
Nanoencapsulation of flufenamic acid has 
significantly increased drug transport and 
accumulation in the skin. 
Luengo et al., 
2006 
Flurbiprofen  NLC NLC formulation of flurbiprofen was led to the 
increase in drug permeation with respect to its 
conventional solution. 
Gonzales-Mira 
et al., 2011 
Flurbiprofen SLN SLN dispersion and gel formulation showed a 
sustained drug release over 24 h period. 
Jain et al., 2005 
Indomethacin NLC  Prolonged in vivo anti-inflammatory activity of 
indomethacin was observed with NLC hydrogels 
compared to its aqueous solution and hydro-
alcoholic gel. 
Ricci et al., 2005 
Indomethacin Nanocapsule Transdermal delivery of indomethacin with poly 
n-butylcyanoacrylate nanocapsules was 
improved with respect to conventional gel 
formulation. 
Miyazaki et al., 
2003 
Ketoprofen SLN Ketoprofen loaded SLN formulations showed a 
prologed anti-inflammatory effect compared to 
its solution. 
Puglia et al., 
2008 
Ketorolac NLC NLC formulation of ketorolac exhibited a 
sustained drug release pattern due to form a 
drug reservoir into skin. **requires rewriting** 
Puglia et al., 
2006 
Nimesulide Nanocapsule 
/nanoemulsion / 
nanospheres 
Nimesulide-loaded nanocarriers formulated in 
hydrophilic gels exhibited good physico-
chemical properties for its dermal 
administration.  
Alves et al., 2005 
Nimesulide Nanocapsule 
/nanoemulsion / 
nanospheres 
Following the application of gel formulations of 
nimesulide based on nanocarriers was detected 
viable epidermis compared to conventional gel 
formulations. 
Alves et al., 2005 
Table 5. Studies on the development of nanocarriers of NSAIDs to improve their skin 
permeability.  
5. Conclusions 
During the last two decades, skin has been shown to be a suitable delivery site for drugs 
that are formulated dermally. Researchers have been trying to overcome gastrointestinal 
side effects by dermal and transdermal delivery of NSAIDs. Dermal administration of 
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NSAIDs enables local drug delivery to diseased tissues and obtains high drug concentration 
in the application site. Dermal application seems to offer an alternative application route for 
preventing systemic side effects of NSAIDs. However, SC is a highly effective barrier and 
challenging for absorption of drugs through skin and drugs may not accumulate properly in 
the target tissues. The most popular strategy is to include chemical enhancers into dermal 
and transdermal formulations to enhance skin delivery of drugs. However, it is difficult to 
choose a penetration enhancer, and to date no penetration enhancer has been proven to be 
ideal. Another approach to improve skin permeation is to develop novel drug carrier 
systems of NSAIDs, in addition to the conventional dosage forms. Microemulsions and nano 
carriers are the most frequently preferred carrier systems for NSAIDs. These new carrier 
systems ensure drug permeation to deeper layers of the skin and reach the synovial fluid. 
These new drug delivery approaches are jointly aiming at minimizing drug dose, diverting 
drugs to the target tissue, and enhancing efficacy in patients. The findings seem to be 
promising and it can be anticipated that the commercial novel carrier systems, providing 
localization of drugs in viable epidermis and dermis layers of skin, could come into the 
market. Thus, by employing these novel systems we may achieve a critical leap forward in 
the safe administration of NSAIDs.  
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